aTyr Pharma (LIFE) Earns News Sentiment Score of 0.03

News coverage about aTyr Pharma (NASDAQ:LIFE) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.6827812506478 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

NASDAQ LIFE traded down $0.10 on Thursday, hitting $2.45. The company’s stock had a trading volume of 38,630 shares, compared to its average volume of 43,924. aTyr Pharma has a 1-year low of $2.30 and a 1-year high of $6.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 8.37 and a current ratio of 8.37. The stock has a market cap of $75.98, a P/E ratio of -1.34 and a beta of 3.48.

How to Become a New Pot Stock Millionaire

Several equities analysts have issued reports on LIFE shares. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Friday, March 9th. JPMorgan Chase cut shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. aTyr Pharma currently has a consensus rating of “Hold” and a consensus target price of $4.67.

COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at

aTyr Pharma Company Profile

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.

Leave a Reply